Table 3.

Serological and IFNγ-T cell immune response.

Participant	N	Time-point 1: 2-16w post 2nd vaccine		Time-point 2: ~6m post 2nd vaccine		Time-point 3: 1-16w post 3rd vaccine
		IgG response	T cell response	IgG response	T cell response	IgG response	T cell response
Untreated	1	+	+
	2					+	+
	3					+	+
	4			+	+
	5	+	+
Cladribine	1			+	+
Dimethyl	1	+	+
Fumarate	2	+	+
	3					+	+
Fingolimod	1	+	–			+	–
	2	+	–
	3	–	+
	4	–	–
	5					–	–
	6					–	–
	7					–	–
Ponesimod	1	+	+
Siponimod	1	+	+
Glat. Acetate	1	+	+
IFNβ (Rebif)	1	+	+
Methotrexte	1	+	+
Natalizumab	1	+	+
	2	+	+
	3	+	+
	4	+	+
Ocrelizumab	1	–	+
	2	+	+
	3	–	+			–	+
	4	–	+
	5					–	+
	6					–	+
	7					+	+
	8			–	+
	9					+	–
	10					+	+
	11					+	+
Ofatumumab	1	+	+
	2	+	+			+	+
Teriflunomide	1					+	–
Healthy	1	+	+
	2	+	+
	3	+	+
	4	+	+
	5	+	+
	6	+	+
	7					+	+
	8					+	+

+: IgG≥ 50 AU/ml serology, or ≥ 25 pg/ml of Spike-specific IFNγ response. -: IgG<50AU/ml serology, or <25 pg/ml of Spike-specific IFNγ response.